La vendita allo scoperto per United Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di United Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

United Therapeutics (NASDAQ:UTHR) Azioni, Report sulle vendite allo scoperto

United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Neutral and raises the price target from $243 to $302.

News

Price Target

Analyst Ratings

UTHR

Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $302

Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform and raises the price target from $575 to $600.

Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $600

Argus Research analyst Jasper Hellweg maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $360 to $400.

Argus Research Maintains Buy on United Therapeutics, Raises Price Target to $400

HC Wainwright &amp; Co. analyst Andrew Fein maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $400 to $425.

HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.39 per share which missed the analyst consensus estimate of $6.43 by 0.62 percent. This is a 18.77 percent increase over earnings of $5.38 per share from the same period last year. The company reported quarterly sales of $748.90 million which beat the analyst consensus estimate of $722.91 million by 3.60 percent. This is a 22.89 percent increase over sales of $609.40 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

United Therapeutics Q3 2024 GAAP EPS $6.39 Misses $6.43 Estimate, Sales $748.90M Beat $722.91M Estimate

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that United Therapeutics will report an earnings per share (EPS) of $6.42.
The announcement from United Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.55, which was followed by a 4.63% increase in the share price the next day.
Here's a look at United Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>6.40</td>
<td>5.65</td>
<td>4.19</td>
<td>5.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.85</td>
<td>6.17</td>
<td>4.36</td>
<td>5.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730224872_0.png" alt="eps graph" />
<h3>Tracking United Therapeutics's Stock Performance</h3>
Shares of United Therapeutics were trading at $349.71 as of October 28. Over the last 52-week period, shares are up 56.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on United Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding United Therapeutics.
A total of 6 analyst ratings have been received for United Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $411.17, suggesting a potential 17.57% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Natera, Genmab and Biomarin Pharmaceutical, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Natera, with an average 1-year price target of $140.58, suggesting a potential 59.8% downside.</li>
<li>For Genmab, analysts project an Buy trajectory, with an average 1-year price target of $46.83, indicating a potential 86.61% downside.</li>
<li>Biomarin Pharmaceutical is maintaining an Outperform status according to analysts, with an average 1-year price target of $100.85, indicating a potential 71.16% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Natera, Genmab and Biomarin Pharmaceutical, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Therapeutics</td>
<td>Buy</td>
<td>19.85%</td>
<td>$637.10M</td>
<td>5.04%</td>
</tr>
<tr>
<td>Natera</td>
<td>Buy</td>
<td>58.13%</td>
<td>$243.17M</td>
<td>-4.59%</td>
</tr>
<tr>
<td>Genmab</td>
<td>Buy</td>
<td>29.58%</td>
<td>$5.21B</td>
<td>4.44%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical</td>
<td>Outperform</td>
<td>19.61%</td>
<td>$581.57M</td>
<td>2.07%</td>
</tr>
</tbody>
</table>

Key Takeaway:
United Therapeutics ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>Unveiling the Story Behind United Therapeutics</h3>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Insights: United Therapeutics</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 19.85%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: United Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's ROE excels beyond industry benchmarks, reaching 5.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<a href="https://www.benzinga.com/quote/UTHR/earnings">To track all earnings releases for United Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For United Therapeutics

Throughout the last three months, 7 analysts have evaluated United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for United Therapeutics, revealing an average target of $409.57, a high estimate of $575.00, and a low estimate of $280.00. This upward trend is evident, with the current average reflecting a 18.57% increase from the previous average price target of $345.43.
<img src="https://www.benzinga.com/files/images/story/2024/1729537256_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive United Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Eun Yang</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$432.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$280.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of United Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Get to Know United Therapeutics Better</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Milestones: United Therapeutics's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.85%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 38.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): United Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.04%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.21%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 7 Analyst Evaluations For United Therapeutics

7 analysts have shared their evaluations of United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for United Therapeutics, revealing an average target of $409.57, a high estimate of $575.00, and a low estimate of $280.00. Observing a 18.57% increase, the current average has risen from the previous average price target of $345.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1729537214_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of United Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Eun Yang</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$432.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$280.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of United Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>About United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>A Deep Dive into United Therapeutics's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.85%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.04%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): United Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 4.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.09, United Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 7 Takes On United Therapeutics

TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $350 to $400.

TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $400

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has outperformed the market over the past 5 years by 19.6% on an annualized basis producing an average annual return of 33.66%. Currently, United Therapeutics has a market capitalization of $15.89 billion. 
Buying $100 In UTHR: If an investor had bought $100 of UTHR stock 5 years ago, it would be worth $436.38 today based on a price of $357.10 for UTHR at the time of writing.
<h3>United Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729020623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today

United Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NYSE">UTHR</a>) short percent of float has fallen 45.25% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 6.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>United Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728574214_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing United Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, United Therapeutics's peer group average for short interest as a percentage of float is 5.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into United Therapeutics's Recent Short Interest

<ul>
<li>U.S. Supreme Court denied United Therapeutics' petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalid</li>
<li>Decisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now final and not subject to further appeal</li>
</ul>
MORRISVILLE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=oaynu9ABuYjMqtlNQpvmoVzKrD4eF90MCZ7PdkPQXAJ_2jBM8MgL2x17_sTtNGFwYSkowt61k7mErinEsg0gy8Mh_95cO0RE-4PuWLO65zQ=">Liquidia Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases,&nbsp;today announced that the United States Supreme Court has rejected United Therapeutics' (UTHR) petition for a writ of certiorari, which requested permission to appeal prior decisions which found that all claims of &nbsp;U.S.&nbsp;Patent No. 10,716,793 (‘793 Patent) are unpatentable due to prior art. As a result, the decision by the Patent Trial and Appeal Board (PTAB) in July 2022, which was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;(Federal Circuit) in December 2023, is now final and not subject to further appeal.

Legal

LQDA

U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To Further Appeal

In the current market session, United Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) stock price is at $350.07, after a 0.68% decrease. However, over the past month, the company's stock went up by 0.02%, and in the past year, by 49.39%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_0.png" alt="Past Year Chart" />

<h3>United Therapeutics P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 61.21 in the Biotechnology industry, United Therapeutics Inc. has a lower P/E ratio of 16.2. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into United Therapeutics Inc's Price Over Earnings

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has outperformed the market over the past 5 years by 20.7% on an annualized basis producing an average annual return of 34.64%. Currently, United Therapeutics has a market capitalization of $15.82 billion. 
Buying $1000 In UTHR: If an investor had bought $1000 of UTHR stock 5 years ago, it would be worth $4,364.49 today based on a price of $355.59 for UTHR at the time of writing.
<h3>United Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727186420_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today

Data from the&nbsp;BREEZE&nbsp;open-label extension study of Tyvaso DPI&nbsp;detail its long-term outcomes and dosing in patients with pulmonary arterial hypertension.

United Therapeutics Plans Five Presentations And One Poster Across Its Commercial And Development Portfolio At The CHEST 2024 Annual Meeting

Analysts' ratings for United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $389.78, accompanied by a high estimate of $575.00 and a low estimate of $280.00. This current average reflects an increase of 18.99% from the previous average price target of $327.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1727110819_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of United Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eun Yang</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$432.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$280.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of United Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Insights: United Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, United Therapeutics showcased positive performance, achieving a revenue growth rate of 19.85% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From United Therapeutics Analyst Ratings

Jefferies analyst Eun Yang maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $315 to $432.

Jefferies Maintains Buy on United Therapeutics, Raises Price Target to $432

Foghorn Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fhtx#NASDAQ">FHTX</a>) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock&#39;s 43.2% gain over the past four weeks.
Last month, the company announced robust financial results for the second quarter of 2024. Studies on the company&#39;s pipeline candidates for treating various oncology indications are progressing well. This might have been driving the share price rally.
This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -20.6%. Revenues are expected to be $7.01 million, down 59.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Foghorn Therapeutics, the consensus EPS estimate for the quarter has been revised 7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn&#39;t usually translate into price appreciation. So, make sure to keep an eye on FHTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy).
Foghorn Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uthr#NASDAQ">UTHR</a>), closed the last trading session 0.6% lower at $339.12. Over the past month, UTHR has returned 5.6%.
For United Therapeutics, the consensus EPS estimate for the upcoming report has changed +0.1% over the past month to $6.33. This represents a change of +17.7% from what the company reported a year ago. United Therapeutics currently has a Zacks Rank of #3 (Hold).
<a href="https://www.zacks.com/stock/news/2336199/strength-seen-in-foghorn-therapeutics-fhtx-can-its-9-5-jump-turn-into-more-strength?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2336199">To read this article on Zacks.com click here.</a>

Biotech

Large Cap

Small Cap

General

FHTX

Strength Seen in Foghorn Therapeutics: Can Its 9.5% Jump Turn into More Strength?

Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz Inc. (Sandoz) and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, LLC (formerly known as RareGen), a wholly owned subsidiary of Liquidia (Liquidia PAH), partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection.

Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M

Federal regulators are grappling with a significant backlog of factory inspections for drug manufacturing, with many facilities not reviewed since before the pandemic.
An analysis by The Associated Press of FDA data revealed that approximately 42% of the 4,700 registered plants have not undergone FDA surveillance inspections since 2019.
These facilities produce crucial medicines such as antibiotics, blood thinners, and cancer therapies, raising concerns over potential contamination and quality issues.
An AP analysis reveals that approximately 2,000 pharmaceutical manufacturers have not undergone FDA surveillance inspections since before the pandemic. This oversight raises potential contamination risks and other safety issues in medications.
A scholar from Duke University expressed concerns about generic drugmakers reducing costs at the expense of quality, which remains unchecked without proper inspections in an ABC News report.
Tainted medications, like the 2022 incident involving antibiotic-resistant bacteria in eyedrops from an Indian factory, underscore the risks of insufficient oversight.
These factories, particularly in India and China, are critical suppliers of low-cost prescription ingredients in the U.S.
Despite the challenges, FDA Associate Commissioner Michael Rogers <a target="_blank" href="https://abcnews.go.com/Health/wireStory/2000-drug-manufacturing-plants-overdue-fda-inspections-after-113414456" rel="noreferrer noopener">asserted</a> that the FDA is the world&#8217;s most stringent drug regulator. However, he acknowledged that inspection rates are still nearly 40% lower than pre-COVID levels, with no set timeline for clearing the backlog.
The situation is exacerbated by staffing challenges, with many experienced inspectors leaving for more flexible job opportunities.
Internationally, the FDA has been using video and online tools for preliminary assessments, but these do not substitute for physical inspections.
The Government Accountability Office has consistently marked this area as high-risk, signaling that more proactive measures are necessary. In the meantime, the FDA focuses on a risk-based approach to prioritize inspections that pose the greatest public health risk.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40750262/mpox-vaccines-challenges-persist-as-congo-receives-first-batch-of-doses-almost-2-years-after-it-d" target="_blank" rel="noreferrer noopener">Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic</a>.</li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

BMRN

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

Analyst Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics (UTHR – Research Report) and keeping the price target at $400.00....

Buy Rating for United Therapeutics Driven by Strong Financial Performance and Strategic Market Positioning

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on United Therapeutics (UTHR – Research Report), boosting the price target to $425.0...

United Therapeutics: Strategic Contracts and Tyvaso Performance Drive Buy Rating and Increased Price Target

H.C. Wainwright analyst Andrew Fein raised the firm's price target on United Therapeutics (UTHR) to $425 from $400 and keeps a Buy rating on the sh...

United Therapeutics price target raised to $425 from $400 at H.C. Wainwright

Argus analyst Jasper Hellweg raised the firm's price target on United Therapeutics (UTHR) to $400 from $360 and keeps a Buy rating on the shares. T...

United Therapeutics price target raised to $400 from $360 at Argus

Healthcare Investing Finding Growth Beyond Pharmaceuticals

Mid-cap stocks with 'significant scope' to upside – WF

United Therapeutics: One To Believe In Despite Competitive Threats

United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom

Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

AGNG

ARKG

BMED

BURL

CACI

CNCR

CRWD

CTRA

EDOC

FERG

FHLC

FTXH

GEHC

GNOM

GWRE

HART

HELX

HTEC

HUBS

IBBQ

IDNA

IDXX

ISRG

LABU

MDEV

MDYG

MPWR

MUSA

NBIX

PFGC

PILL

PINK

PSCH

PSTG

ROST

RSPH

SBIO

SPOT

TRGP

VEEV

WDNA

Press Releases

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

Comments

United Therapeutics

Vendite allo scoperto

United Therapeutics (NASDAQ:UTHR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO